Month: June 2020

Jason Fraser To Be Appointed CFODonna Titzman To RetireSAN ANTONIO, June 19, 2020 (GLOBE NEWSWIRE) — Valero Energy Corporation (NYSE: VLO) today announced that Jason Fraser, who has served as Valero’s Executive Vice President and General Counsel since January 2019, has been appointed by Valero’s Board of Directors to serve as the Company’s Executive Vice President and Chief Financial Officer, effective July 15, 2020. Mr. Fraser will succeed Donna Titzman, who will remain as Executive Vice President and Chief Financial Officer until her retirement from the position on the same date, and will continue with the Company for a transitional period thereafter.Richard Walsh, Valero’s current Vice President and Deputy General Counsel, will be promoted to Senior Vice President and will succeed Mr. Fraser as General Counsel, effective July...

HAMILTON, BERMUDA, June 19, 2020 – DHT Holdings, Inc. (NYSE:DHT) (“DHT”) announces the results of its 2020 Annual Meeting of Shareholders (the “Annual Meeting”).The Annual Meeting was held virtually on Thursday, June 18, 2020.  At the Annual Meeting, the shareholders voted to elect Jeremy Kramer as Class I Director for a term of three years and to ratify the selection of Deloitte AS as DHT’s independent registered public accounting firm for the fiscal year ending December 31, 2020.About DHT Holdings, Inc.DHT is an independent crude oil tanker company. Our fleet trades internationally and consists of crude oil tankers in the VLCC segment. We operate through our integrated management companies in Monaco, Singapore and Oslo, Norway. You shall recognize us by our business approach with an experienced organization with focus on first rate...

SAN DIEGO, June 19, 2020 (GLOBE NEWSWIRE) — Obalon Therapeutics, Inc. (Nasdaq: OBLN), a weight loss solutions company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for the first quarter ended March 31, 2020 and provided a business update.Financial results for the first quarter of 2020Revenue for the first quarter of 2020 was $0.8 million, compared to $1.8 million for the first quarter of 2019. Net loss for the first quarter of 2020 was $5.3 million, compared to $8.3 million for the first quarter of 2019. Net loss per share for the first quarter of 2020 was $0.68, compared to $3.59 for the first quarter of 2019.Cost of revenue was $0.5 million for the first quarter of 2020, down from $1.2 million for the first quarter of...

UAB Ignitis Grupė, (hereinafter – Ignitis Grupė or the Company) identification code 301844044, registered office placed at Žvejų str. 14, Vilnius, Republic of Lithuania. The total nominal value of issued bonds 900 000 000 EUR; ISIN codes XS1646530565; XS1853999313; XS2177349912.On June 19, 2020 the Supervisory Board of the Company approved updated long-term corporate strategy (hereinafter – the Strategy) of Ignitis Group (hereinafter – the Group) and strategic plan for the period 2020–2023.The Strategy update follows the renewed letter of expectations from the Company’s sole shareholder–Ministry of Finance of the Republic of Lithuania. This letter is published on the website of the Company, at https://ignitisgrupe.lt/en/shareholders.Commitment to the decarbonisation, the modernization of the energy system, the development of renewable...

UAB „Ignitis grupė“ (toliau – „Ignitis grupė“ ir Bendrovė), juridinio asmens kodas: 301844044, registruotos buveinės adresas: Žvejų g. 14, Vilnius. Bendra UAB „Ignitis grupė“ išleistų obligacijų nominali vertė 900 000 000 EUR; ISIN kodai: XS1646530565; XS1853999313; XS2177349912.2020 m. birželio 19 d. Bendrovės stebėtojų taryba patvirtino atnaujintą ilgalaikę „Ignitis grupės“ įmonių grupės (toliau – Grupė) veiklos strategiją (toliau – Strategija) ir 2020–2023 m. laikotarpio strateginį planą.Strategijos atnaujinimas paremtas atnaujintu akcininko lūkesčių raštu, kurį Bendrovei pateikė jos vienintelio akcininko teises įgyvendinanti Lietuvos Respublikos finansų ministerija. Su šiuo raštu galima susipažinti Bendrovės svetainėje, adresu: https://www.ignitisgrupe.lt/lt/akcininkai.Didžiausias dėmesys įgyvendinant atnaujintą Grupės strategiją...

RANCHO CUCAMONGA, Calif., June 19, 2020 (GLOBE NEWSWIRE) — Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO, Dan Dischner, Vice President of Corporate Communications and Human Resources, and Tony Marrs, Sr. Vice President Regulatory Affairs and Clinical Operations will be presenting at BMO Prescriptions for Success Healthcare Conference on Tuesday, June 23, 2020 at 1:00 p.m. Eastern Time.This presentation will be made available with a live webcast and may be accessed by visiting Amphastar’s Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 90 days following the presentation.About Amphastar:Amphastar is a specialty pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary...

VAN NUYS, Calif., June 19, 2020 (GLOBE NEWSWIRE) — Eco Innovation Group, Inc.  (“ECOX” or the “Company”) (OTC: ECOX), an innovative company aggregating investments in new technologies that are environmentally friendly, promote green energy and are socially responsible, announced today that it is moving from Stage 3 testing for its latest energy saving innovation called PoolCooled™.ECOX uses a 9 Step Process to Market Successfully determine if a new product merits acceptance by the Company:Idea GenerationIdea ScreeningConcept Development and TestingMarket Strategy DevelopmentBusiness AnalysisProduct licensing and/or deal structure with the inventor/innovatorProduct DevelopmentTest Marketing/PromotionCommercializationThe PoolCooled™ product utilizes proprietary technologies to take cool water from an existing...

Key PointsImmuron executes a Research Agreement with The Henry M. Jackson Foundation for Advancement of Military Medicine Inc.Immuron executes a Research Agreement with CSIRO to develop a new oral therapeutic targeting Campylobacter and ETEC for clinical evaluationVaccination program initiatedNMRC submits Pre-Investigational New Drug (IND) information package to FDANMRC plans to file an IND application with FDATwo human phase II clinical trials to be conducted in 2021One trial will focus on the ability of the hyperimmune product to protect volunteers against moderate to severe campylobacteriosisThe second trial will focus on ETEC infectionsMELBOURNE, Australia, June 19, 2020 (GLOBE NEWSWIRE) — Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercialising oral immunotherapeutics...

SAN DIEGO, 19 juin 2020 (GLOBE NEWSWIRE) — Crown Bioscience a annoncé aujourd’hui la tenue de sa conférence et son salon commercial innovants AACR 2020. L’événement virtuel, qui se déroulera du 22 au 25 juin, intègrera toutes les caractéristiques d’une conférence scientifique majeure, avec des intervenants principaux, un accès aux affiches AACR 2020 de CrownBio, ainsi qu’un stand au salon commercial.Pour coïncider avec la 2e réunion annuelle virtuelle de l’AACR, ce forum unique comprendra la publication des 13 affiches internes et collaboratives de CrownBio pour l’AACR 2020, couvrant une variété de sujets portant sur l’oncologie préclinique et l’immuno-oncologie, notamment les organoïdes tumoraux et l’ingénierie organoïde, l’imagerie syngénique et les homogreffes des tumeurs,...

SAN DIEGO, June 19, 2020 (GLOBE NEWSWIRE) — Crown Bioscience hat heute seine innovative AACR 2020 Konferenz und Messe angekündigt. Die virtuelle Veranstaltung vom 22. bis 25. Juni bietet alles, was eine große wissenschaftliche Konferenz auch zu bieten hat: Keynote-Speaker, Zugang zu AACR 2020 Postern von CrownBio sowie einen Messestand.Auf diesem einzigartigen Forum, das gleichzeitig mit dem AACR Virtual Annual Meeting II stattfindet, werden 13 interne und gemeinschaftliche AACR 2020 Poster von CrownBio veröffentlicht. Diese decken eine Reihe von präklinischen Onkologie- und Immunonkologie-Themen ab: Tumor-Organoide und Organoid Engineering, syngene Bildgebung und Tumor-Homografts sowie neuartige humanisierte Wirkstoffzielmodelle. Zudem können die Posterautoren alle Fragen der Teilnehmer direkt beantworten.Die Teilnahme an der Veranstaltung...